Categories
Change Password!
Reset Password!
This single-center retrospective cohort study was carried out to indirectly compare the tolerability, efficacy, and safety of guselkumab and risankizumab (interleukin-23 inhibitors) for psoriasis management in real world practice.
In patients diagnosed with
moderate-to-severe psoriasis, both guselkumab and risankizumab showed favorable
efficacy and safety profile.
This single-center retrospective
cohort study was carried out to indirectly compare the tolerability, efficacy,
and safety of guselkumab and risankizumab (interleukin-23 inhibitors) for
psoriasis management in real world practice.
The study recruited 68 people
suffering from psoriasis. Participants were managed with either a standard dose
of guselkumab (n=36; 100 mg given by subcutaneous injection at week 0 and week
four, followed by a maintenance dose every eight weeks) or with a standard dose
of risankizumab (n=32; two injections of 75 mg subcutaneously at week 0, week
four, and then every twelve weeks).
The study groups were found to be comparable for all the evaluated characteristics, except for the mean psoriasis duration that was greater for guselkumab. Table 1 shows a decline in mean Psoriasis Area and Severity Index (PASI) at the baseline, week 28 and week 44.
No inter-group profound differences were noted in mean PASI and body
surface area. In
both guselkumab and risankizumab groups, no cases of severe adverse events,
cardiovascular events, injection site reaction, malignancy, and candida were
noted.
In real world practice, both risankizumab
and guselkumab demonstrated favorable efficacy and safety profile, being
comparable in terms of PASI100 and PASI90 responses as well as in the frequency
of adverse events and discontinuation rates.
Dermatologic Therapy
Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study
Angelo Ruggiero et al.
Comments (0)